131 related articles for article (PubMed ID: 26098842)
1. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Butzke B; Oduncu FS; Severin F; Pfeufer A; Heinemann V; Giessen-Jung C; Stollenwerk B; Rogowski WH
Acta Oncol; 2016; 55(3):318-28. PubMed ID: 26098842
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.
Gold HT; Hall MJ; Blinder V; Schackman BR
Cancer; 2009 Sep; 115(17):3858-67. PubMed ID: 19517472
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
Pichereau S; Le Louarn A; Lecomte T; Blasco H; Le Guellec C; Bourgoin H
J Pharm Pharm Sci; 2010; 13(4):615-25. PubMed ID: 21486535
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer.
Obradovic M; Mrhar A; Kos M
Pharmacogenomics; 2008 May; 9(5):539-49. PubMed ID: 18466101
[TBL] [Abstract][Full Text] [Related]
6. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
Wei X; Cai J; Sun H; Li N; Xu C; Zhang G; Sui Y; Zhuang J; Zheng B
Pharmacogenomics; 2019 Mar; 20(4):241-249. PubMed ID: 30628534
[TBL] [Abstract][Full Text] [Related]
8. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
9. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Tappenden P; Jones R; Paisley S; Carroll C
Eur J Cancer; 2007 Nov; 43(17):2487-94. PubMed ID: 17910914
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
Clin Colorectal Cancer; 2014 Dec; 13(4):219-25. PubMed ID: 25306485
[TBL] [Abstract][Full Text] [Related]
12. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
14. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
Miyata Y; Touyama T; Kusumi T; Morita Y; Mizunuma N; Taniguchi F; Manabe M
Int J Clin Oncol; 2016 Aug; 21(4):696-703. PubMed ID: 26710796
[TBL] [Abstract][Full Text] [Related]
15. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Liu X; Xu W
Pharmacogenomics; 2014 Jun; 15(9):1171-4. PubMed ID: 25141892
[No Abstract] [Full Text] [Related]
20. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G
Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]